Peplin into Phase III

By Dylan Bushell-Embling
Tuesday, 09 September, 2008

Peplin [ASX: PLI] has begun a Phase III trial of its PEP005 gel for solar keratoses, common pre-cancerous skin lesions.

The trial will examine the efficacy of the gel when applied to locations other than the head. It will be simultaneously conducted in sites in Australia and the US.

The trial is being conducted with a Special Protocol Assessment from the US FDA, which ensures that the results of the study may be submitted to the FDA as part of the basis of a new drug application.

Around 250 participants are expected take part in the trial of PEP005, an ingenol mebutate gel.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd